Novartis Access
Showing 1 - 25 of 7,959
GIST and CML Trial in Worldwide (imatinib mesylate)
Active, not recruiting
- GIST and CML
- imatinib mesylate
-
Los Angeles, California
- +28 more
Apr 25, 2022
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program Trial in Worldwide
Recruiting
- Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
- Previously treated CAR-T patients
-
Phoenix, Arizona
- +71 more
Nov 14, 2022
Cardiovascular Disease, Diabetes Type II, Breast Cancer Trial (Novartis Access)
Completed
- Cardiovascular Disease
- +3 more
- Novartis Access
- (no location specified)
Apr 27, 2020
Severe/Very Severe COVID-19 Illness Trial (Ruxolitinib)
No longer available
- Severe/Very Severe COVID-19 Illness
- (no location specified)
Jan 22, 2021
Heart Failure With Reduced Ejection Fraction (HF-rEF) Trial in Worldwide (LCZ696)
No longer available
- Heart Failure With Reduced Ejection Fraction (HF-rEF)
-
Vero Beach, Florida
- +288 more
Feb 10, 2021
Development of Novel Clinical Endpoints in Intermediate AMD
Active, not recruiting
- Age Related Macular Degeneration (AMD)
- No intervention
-
Copenhagen, Denmark
- +19 more
May 23, 2022
Advanced Solid Tumors Which Are cMET-dependent Trial in Worldwide (Capmatinib, Nazartinib, Gefitinib)
Recruiting
- Advanced Solid Tumors Which Are cMET-dependent
- Capmatinib
- +3 more
-
Boston, Massachusetts
- +12 more
Jan 27, 2023
Cushing's Disease, Acromegaly, Neuroendocrine Tumors Trial in Worldwide (Pasireotide, Cabergoline)
Active, not recruiting
- Cushing's Disease
- +8 more
-
La Jolla, California
- +93 more
May 19, 2022
Paroxysmal Nocturnal Hemoglobinuria Trial in Worldwide (Iptacopan)
Recruiting
- Paroxysmal Nocturnal Hemoglobinuria
-
Brno - Bohunice, Czechia
- +30 more
Jul 29, 2022
Non-Tuberculous Mycobacterial (NTM) Infections Trial in Canada, United States (Lamprene®/Clofazimine)
Available
- Non-Tuberculous Mycobacterial (NTM) Infections
- (no location specified)
Dec 14, 2022
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia Trial in Uijeongbu si (Asciminib single agent, Asciminib, Imatinib)
Recruiting
- Chronic Myelogenous Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Asciminib single agent
- +5 more
-
Ann Arbor, Michigan
- +49 more
Jan 26, 2023
Chronic Spontaneous Urticaria (CSU) Trial (LOU064 (blinded), Placebo, LOU064 (open label))
Not yet recruiting
- Chronic Spontaneous Urticaria (CSU)
- LOU064 (blinded)
- +2 more
- (no location specified)
Aug 22, 2022
Autoimmunity, Inflammation Trial in Worldwide (Secukinumab s.c. injection)
Recruiting
- Autoimmunity, Inflammation
- Secukinumab s.c. injection
-
Fullerton, California
- +93 more
Jul 14, 2022
Cancer, Tumors, Tumor Trial in Netherlands (Panitumumab, Olaparib, Dabrafenib)
Recruiting
- Cancer
- +3 more
- Panitumumab
- +32 more
-
Amersfoort, Utrecht, Netherlands
- +34 more
Oct 26, 2021